黑色素瘤衍生的介质可以促进前转移龛：淋巴转移的十字路口。
Melanoma-derived mediators can foster the premetastatic niche: crossroad to lymphatic metastasis.
机构信息
Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Department of Oncology, Mayo Clinic, Rochester, MN, USA; Mayo Clinic Cancer Center, Mayo Clinic, Rochester, MN, USA.
出版信息
Trends Immunol. 2023 Sep;44(9):724-743. doi: 10.1016/j.it.2023.07.002. Epub 2023 Aug 10.
Abstract
The natural history of advanced malignant melanoma demonstrates that, in most cases, widespread tumor dissemination is preceded by regional metastases involving tumor-draining lymph nodes [sentinel lymph nodes (SLNs)]. Under physiological conditions, LNs play a central role in immunosurveillance to non-self-antigens to which they are exposed via afferent lymph. The dysfunctional immunity in SLNs is mediated by tumor secretory factors that allow the survival of metastatic melanoma cells within the LN by creating a premetastatic niche (PMN). Recent studies outline the altered microenvironment of LNs shaped by melanoma mediators. Here, we discuss tumor secretory factors involved in subverting tumor immunity and remodeling LNs and highlight emerging therapeutic strategies to reinvigorate antitumoral immunity in SLNs.
摘要
晚期恶性黑色素瘤的自然病程表明，在大多数情况下，广泛的肿瘤播散之前，区域转移会累及引流肿瘤的淋巴结[前哨淋巴结 (SLN)]。在生理条件下，淋巴结在针对其通过输入淋巴管暴露的非自身抗原的免疫监视中发挥核心作用。SLN 中的功能障碍性免疫是由肿瘤分泌因子介导的，这些因子通过创建预先转移的生态位 (PMN)，允许转移黑色素瘤细胞在淋巴结内存活。最近的研究概述了由黑色素瘤介质塑造的改变的淋巴结微环境。在这里，我们讨论了参与颠覆肿瘤免疫和重塑淋巴结的肿瘤分泌因子，并强调了新兴的治疗策略，以重新激活 SLN 中的抗肿瘤免疫。
相似文献
1
Melanoma-derived mediators can foster the premetastatic niche: crossroad to lymphatic metastasis.
Trends Immunol. 2023 Sep;44(9):724-743. doi: 10.1016/j.it.2023.07.002. Epub 2023 Aug 10.
2
Melanoma-Derived Extracellular Vesicles Induce CD36-Mediated Pre-Metastatic Niche.
Biomolecules. 2024 Jul 11;14(7):837. doi: 10.3390/biom14070837.
3
The interplay between tumor and nodal microenvironments for the formation of nodal premetastatic niche in head and neck cancer.
Am J Physiol Cell Physiol. 2023 Dec 1;325(6):C1516-C1531. doi: 10.1152/ajpcell.00337.2023. Epub 2023 Nov 6.
4
Tumor-induced lymphangiogenesis in cervical lymph nodes in oral melanoma-bearing mice.
J Exp Clin Cancer Res. 2012 Oct 2;31(1):83. doi: 10.1186/1756-9966-31-83.
5
Cutaneous lymphatic drainage in patients with grossly involved nodal basins.
Ann Surg Oncol. 1999 Jun;6(4):345-9. doi: 10.1007/s10434-999-0345-4.
6
Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma.
J Clin Oncol. 2008 Sep 10;26(26):4296-303. doi: 10.1200/JCO.2007.15.4179. Epub 2008 Jul 7.
7
Tumor lymphangiogenesis and melanoma metastasis.
J Cell Physiol. 2008 Aug;216(2):347-54. doi: 10.1002/jcp.21494.
8
Melanoma-derived extracellular vesicles mediate lymphatic remodelling and impair tumour immunity in draining lymph nodes.
J Extracell Vesicles. 2022 Feb;11(2):e12197. doi: 10.1002/jev2.12197.
9
From tumor lymphangiogenesis to lymphvascular niche.
Cancer Sci. 2009 Jun;100(6):983-9. doi: 10.1111/j.1349-7006.2009.01142.x. Epub 2009 Feb 20.
10
Factors predictive of pelvic lymph node involvement and outcomes in melanoma patients with metastatic sentinel lymph node of the groin: A multicentre study.
Eur J Surg Oncol. 2015 Jul;41(7):823-9. doi: 10.1016/j.ejso.2015.02.005. Epub 2015 Mar 11.
引用本文的文献
1
Confronting Melanoma Radioresistance: Mechanisms and Therapeutic Strategies.
Cancers (Basel). 2025 Aug 14;17(16):2648. doi: 10.3390/cancers17162648.
2
Characterizing spatial immune architecture in metastatic melanoma using high-dimensional multiplex imaging.
Front Immunol. 2025 Apr 29;16:1560778. doi: 10.3389/fimmu.2025.1560778. eCollection 2025.
3
Unleashing the therapeutic potential of tumor-draining lymph nodes: spotlight on bladder cancer.
J Transl Med. 2025 Apr 29;23(1):489. doi: 10.1186/s12967-024-05864-7.
4
Predictive Factors for Sentinel Lymph Node Positivity in Melanoma Patients-The Role of Liquid Biopsy, MicroRNA and Gene Expression Profile Panels.
Cancers (Basel). 2025 Apr 10;17(8):1281. doi: 10.3390/cancers17081281.
5
Melanoma-derived cytokines and extracellular vesicles are interlinked with macrophage immunosuppression.
Front Mol Biosci. 2025 Jan 22;11:1522717. doi: 10.3389/fmolb.2024.1522717. eCollection 2024.
6
Biomimetic intelligent nanoplatform with cascade amplification effect for tumor synergy therapy.
Sci Rep. 2024 Dec 28;14(1):31067. doi: 10.1038/s41598-024-82291-0.
7
Metabolic insights into tumor lymph node metastasis in melanoma.
Cell Oncol (Dordr). 2024 Dec;47(6):2099-2112. doi: 10.1007/s13402-024-01027-4. Epub 2024 Dec 20.
8
Patient-Derived Melanoma Immune-Tumoroids as a Platform for Precise High throughput Drug Screening.
Adv Sci (Weinh). 2024 Dec;11(48):e2408707. doi: 10.1002/advs.202408707. Epub 2024 Oct 30.
9
Pre-metastatic niche: formation, characteristics and therapeutic implication.
Signal Transduct Target Ther. 2024 Sep 25;9(1):236. doi: 10.1038/s41392-024-01937-7.
10
Current advance of nanotechnology in diagnosis and treatment for malignant tumors.
Signal Transduct Target Ther. 2024 Aug 12;9(1):200. doi: 10.1038/s41392-024-01889-y.
本文引用的文献
1
Localized immune surveillance of primary melanoma in the skin deciphered through executable modeling.
Sci Adv. 2023 Apr 14;9(15):eadd1992. doi: 10.1126/sciadv.add1992. Epub 2023 Apr 12.
2
The Influence of Obesity on Melanoma and Sentinel Lymph Node Diagnosis: A Retrospective Monocentric Study in 1001 Patients.
Cancers (Basel). 2023 Mar 16;15(6):1806. doi: 10.3390/cancers15061806.
3
Immune determinants of the pre-metastatic niche.
Cancer Cell. 2023 Mar 13;41(3):546-572. doi: 10.1016/j.ccell.2023.02.018.
4
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth.
Cancer Cell. 2023 Mar 13;41(3):374-403. doi: 10.1016/j.ccell.2023.02.016.
5
Extracellular vesicles and melanoma: New perspectives on tumor microenvironment and metastasis.
Front Cell Dev Biol. 2023 Jan 10;10:1061982. doi: 10.3389/fcell.2022.1061982. eCollection 2022.
6
CD8 T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor.
Immunity. 2023 Jan 10;56(1):107-124.e5. doi: 10.1016/j.immuni.2022.12.002. Epub 2022 Dec 28.
7
Quantitative spatial evaluation of tumor-immune interactions in the immunotherapy setting of metastatic melanoma lymph nodes.
Front Immunol. 2022 Dec 5;13:1024039. doi: 10.3389/fimmu.2022.1024039. eCollection 2022.
8
Adipocytes Encapsulating Telratolimod Recruit and Polarize Tumor-Associated Macrophages for Cancer Immunotherapy.
Adv Sci (Weinh). 2023 Feb;10(5):e2206001. doi: 10.1002/advs.202206001. Epub 2022 Dec 16.
9
Adrenomedullin Secreted by Melanoma Cells Promotes Melanoma Tumor Growth through Angiogenesis and Lymphangiogenesis.
Cancers (Basel). 2022 Nov 29;14(23):5909. doi: 10.3390/cancers14235909.
10
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
N Engl J Med. 2022 Dec 8;387(23):2113-2125. doi: 10.1056/NEJMoa2210233.
Zotero 插件